MLabs next-generation sequencing (NGS) offerings include Solid Tumor, Lung Cancer, Colorectal Cancer, and Melanoma NGS Panels. These NGS tests target 50 genes to detect substitution and insertion/deletion mutations (35 genes), gene amplifications (19 genes), and gene fusions (21 genes) including NTRK gene fusions involving NTRK1, NTRK2, and NTRK3. The TRK inhibitor Vitrakvi® (larotrectinib) was recently FDA-approved for treatment of adult and pediatric patients with solid tumors that have a NTRK gene fusion. NGS is the most comprehensive method to identify NTRK gene fusions, particularly in cases with minimal available tissue. MLabs performs these panels using as little as <1mm2 tissue with a 4% QNS rate. For more information about our tissue requirements for NGS testing visit Less Tissue More Results.
MLabs NGS panels not only detect NTRK gene fusions, but include many other standard of care and emerging biomarkers in solid tumors. A complete list of genes assessed for mutations, amplifications and fusions is listed below.
|Hotspot Mutation Detection||Amplification||Selected Fusion Detection|
|EGFR||MAP2K2||ERBB2 (HER2)||PDGFRA||FGFR2||ERBB2 (HER2)|